ICVX Stock Price, Chart, Stats & News
ICVX chart
Fundamentals
Gross margin | -216.67% |
Operating margin | -16332.99% |
Pretax margin | -15765.98% |
Net margin | -15198.97% |
Effective tax rate | 3.60% |
ROA | -37.06% |
ROE | -35.64% |
D/E | 0.04x |
Interest coverage ratio | – |
ICVX valuation
P/E | – |
P/S | 1321.37x |
P/B | 2.79x |
P/CF | -9.86x |
P/FCF | -10.57x |
P/OCF | -9.86x |
PEG | -0.07x |
EV multiple | -8.70x |
About
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials.
Similar securities
Based on sector and market capitalization
